Masimo (NSDQ:MASI) announced that it received FDA de novo classification for its Bridge neuromodulation-based opioid withdrawal device. Bridge uses neuromodulation to aid in reducing the symptoms associated with opioid withdrawal. Irvine, Calif.-based Masimo touts it as the first evidence-based, drug-free, non-surgical device of its kind. The wearable, single-patient-use, percutaneous neurostimulator fits behind the ear and applies […]
FDA clears Masimo respiration sensor
Masimo (NSDQ:MASI) announced today that its Centroid wireless orientation, activity and respiration rate sensor received FDA clearance. Centroid is a wearable sensor designed to monitor patient position in an effort to avoid preventable pressure ulcers, while also alerting clinicians to sudden movements, such as fall-like events. The device also detects chest movements to continuously provide respiration […]
Masimo launches monitoring for reopening economy
Masimo recently launched its SafetyNet-Open that is designed to businesses, governments and schools manage employee and student health and safety during the COVID-19 pandemic. The remote patient monitoring solution helps coordinate the continuous monitoring of people through sensors and an app. Its centralized dashboard helps organizations understand patterns that could support contact tracing. The components […]
Philips patient monitors to add more Masimo technology
Masimo (NSDQ:MASI) and Royal Philips (NYSE:PHG) announced today that Philips will integrate additional Masimo measurement technologies into certain IntelliVue MX-series monitors to help clinicians assess cerebral oximetry and ventilation status. Masimo noninvasive measurements, such as SET measure-through motion and Low Perfusion pulse oximetry and advanced rainbow SET Pulse CO-Oximetry parameters like noninvasive hemoglobin (SpHb), have long been […]
Masimo up on Street-beating 1Q
Masimo (NSDQ:MASI) shares inched up today on first-quarter results that topped the consensus forecast. The Irvine, Calif.-based company posted profits of $64 million, or $1.12 per share, on sales of $269.6 million for the three months ended March 28, 2020, for a 30.7% bottom-line gain on sales growth of 16.4%. Adjusted to exclude one-time items, earnings […]
Masimo withdraws 2020 guidance due to COVID-19
Masimo (NSDQ:MASI) announced today that it is updating its preliminary product revenue range for the first quarter but withdrawing its full-year 2020 guidance as a result of the COVID-19 pandemic. The Irvine, Calif.-based non-invasive monitoring technology developer anticipates product revenue in the first quarter of 2020 to range between $265 million and $271 million, reflecting growth […]
Masimo acquires TNI Medical
Non-invasive monitoring technology developer Masimo (NSDQ:MASI) announced that it plans to acquire German ventilation company TNI Medical for an undisclosed amount. Irvine, Calif.-based Masimo pulled the trigger on the acquisition after it disclosed an investment in August 2019 that included an exclusive option to purchase Würzburg, Germany-based TNI. Masimo expects to close the deal in the […]
Masimo gains FDA clearance for new respiration rate measurement system
Masimo (NSDQ:MASI) said today that the FDA has granted 510(k) clearance to its continuous RRp (respiration rate from the photoplethysmograph) monitoring of adult and pediatric patients with Rad-97, Radical-7, and Radius-7 Pulse CO-Oximeters. With this clearance, both continuous and spot-check RRp are now available in the U.S., supported in a variety of pulse oximetry sensors and […]
Masimo claims Apple infringed 10 of its health-monitoring patents
Patient-monitoring company Masimo (NSDQ:MASI) and spinoff company Cercacor filed suit yesterday accusing Apple (NSDQ:AAPL) of poaching its employees and infringing 10 of its patents to improve the health monitoring functions of the Apple Watch. The lawsuit, filed in federal court in California, claims that in 2013, Apple contacted Masimo and asked to meet regarding a […]
Masimo’s improved pulse oximetry tech now available to all U.S. newborns
Masimo (NSDQ:MASI) has won FDA clearance for pulse oximetry sensors with improved oxygen saturation accuracy specifications for newborns over 3 kg in weight. Masimo touted significantly improved performance specifications for the RD SET sensors with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. The improved specs were already available for babies under 3 kg, so […]
Masimo touts study on remote monitoring for desaturation and bradypnea
Masimo (NSDQ:MASI) announced today that its study of the Masimo Patient SafetyNet and rainbow acoustic monitoring (RAM) with RRa revealed that use of monitoring systems might provide a safety net for postoperative patients. Irvine, Calif.-based Masimo’s Patient SafetyNet is a supplemental remote monitoring patient surveillance and clinician notification system designed to work with Masimo and third-party […]
- 1
- 2
- 3
- …
- 21
- Next Page »
